Treatment of Leukemia in Relapse after Bone Marrow Transplantation
- 3 March 1994
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 330 (9) , 645-646
- https://doi.org/10.1056/nejm199403033300918
Abstract
The prognosis of patients with a relapse of leukemia within the first year after allogeneic bone marrow transplantation is dismal. Giralt et al. (Sept. 9 issue)1 described seven patients whose leukemia had relapsed after allogeneic bone marrow transplantation. All were treated with granulocyte colony-stimulating factor (filgrastim) to induce terminal differentiation of the leukemic clone, selectively stimulate donor hematopoietic cells, and enhance the graft-versus-leukemia reaction. Three of the seven patients had a complete response, with reestablishment of hematopoiesis of donor origin. We observed such a trend toward a lower relapse rate in patients treated with recombinant granulocyte-macrophage colony-stimulating factor in a prospective randomized study comparing this factor with placebo in recipients of T-cell-depleted marrow from histocompatible sibling donors2.Keywords
This publication has 1 reference indexed in Scilit: